Hemogenyx Pharmaceuticals (LON:HEMO) Stock Price Up 7.9% – Here’s What Happened

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares shot up 7.9% on Tuesday . The stock traded as high as GBX 1.47 ($0.02) and last traded at GBX 1.47 ($0.02). 5,676,613 shares traded hands during trading, a decline of 39% from the average session volume of 9,259,996 shares. The stock had previously closed at GBX 1.36 ($0.02).

Hemogenyx Pharmaceuticals Stock Performance

The company has a market capitalization of £20.84 million, a P/E ratio of -143.50 and a beta of 3.14. The company has a debt-to-equity ratio of 92.09, a quick ratio of 6.72 and a current ratio of 4.38. The business’s fifty day simple moving average is GBX 1.38 and its 200-day simple moving average is GBX 1.37.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.